ClearPoint Neuro nullifies authorized share decrease after proxy statement error

ClearPoint Neuro, Inc.

At May 24, 2022 Annual Meeting, stockholders approved decreasing authorized shares from 200M to 80M.
Beneficial owner questioned proxy statement inaccuracy on broker discretionary voting for the share decrease proposal.
Company filed Certificate of Correction on June 3, 2022 to nullify the previously filed Certificate of Amendment.
Company will seek stockholder approval again at a future meeting to achieve modest Delaware franchise tax savings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.